Confer

Quick links to important sections

Confer

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Confer

Property Description
Active ingredient Ferrous Fumarate (Fe(C₄H₂O₄))
Form Oral preparation (Tablet or capsule)
Pharmacological class Antianemic agent / Hematinic
Common use Iron replacement therapy / Countering nutritional deficiency
Origin Synthetic compound (Iron salt)

What is Confer and What Type of Medicine Is It?

Confer is a medicinal product whose active ingredient is Ferrous Fumarate, which is chemically defined as an iron salt. It is classified under the pharmacological class of antianemic agents or hematinics. This classification establishes the medicine's role as an oral iron supplement, providing a concentrated source of elemental iron.

The use of the Ferrous Fumarate salt is clinically utilized for iron replenishment therapy. The compound is used as a dietary supplement to prevent or treat low blood levels of iron. Confer is a synthetic compound, manufactured in a standardized pharmaceutical preparation to ensure precise delivery of the active substance.


Composition and Pharmaceutical Form of Confer

Confer is a pharmaceutical preparation most commonly supplied as a tablet or capsule for oral administration. It is typically formulated as a single-active ingredient product, meaning the therapeutic effect comes solely from the Ferrous Fumarate compound, distinguishing it from combination micronutrient products.

This specific dosage form is designed to deliver a measurable and stable dose of iron. Ferrous Fumarate has an established role for addressing iron needs for nutritional purposes. The composition, including the inactive excipients, ensures the proper release of the concentrated elemental iron.


What is the General Therapeutic Purpose of Confer?

The general therapeutic purpose of Confer is to act as a crucial source for iron replacement therapy, helping to counter states of nutritional deficiency. The medicine provides the necessary iron to support the synthesis of hemoglobin (Hb) and promote erythropoiesis (red blood cell production). This foundational action aims to restore the body’s oxygen-carrying capacity, alleviating the general weakness and fatigue often associated with iron deficits.

What side effects are possible with Confer?

Possible side effects and safety information for Confer

Official safety documents for Confer categorize possible unwanted effects based on body system and observed frequency. The overall safety profile highlights that the majority of adverse reactions are mild to moderate in severity.

Key Adverse Reactions and Frequencies

The most frequently reported adverse reactions fall into the Very Common (ge 1/10) category and primarily affect the Nervous and Gastrointestinal Systems. These often include Headache and Nausea.

Reactions categorized as Common (ge 1/100 to < 1/10) typically involve general discomfort and gastrointestinal issues, such as Fatigue, Diarrhea, and local Injection Site Reactions.

Uncommon or less frequent adverse effects can involve the immune system (e.g., Hypersensitivity Reactions) and may include Dizziness or Vomiting.

System-Organ Class Very Common (ge 1/10) Common (ge 1/100 to < 1/10)
Nervous System Disorders Headache Dizziness
Gastrointestinal Disorders Nausea Diarrhea, Vomiting
General Disorders & Admin. Site Fatigue, Injection Site Reaction

Serious and Population-Specific Safety Notes

Official prescribing information alerts to the potential for Serious Hypersensitivity Reactions, including Anaphylaxis and Angioedema, which require immediate medical attention. Severe Hepatic Impairment has also been reported in regulatory documentation as a rare but clinically significant adverse reaction.

Use is contraindicated in patients with a confirmed hypersensitivity to the active substance or its components. Particular caution and monitoring are required in patients with pre-existing Severe Renal Impairment. The official label also notes that safety and efficacy have not been established for the pediatric population. The incidence of some adverse effects, such as gastrointestinal disturbances, has been reported to be dose-dependent in clinical trials.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with this medication as presenting with a range of symptoms affecting multiple body systems. The documented overdose profile includes central nervous system (CNS) disturbances such as lethargy, agitation, confusion, and tremor, alongside gastrointestinal effects, including nausea, vomiting, and diarrhea.

More severe overdose presentations involve significant cardiovascular signs, such as tachycardia and rapid or irregular heartbeat. The risk of life-threatening events, including seizures and coma, is documented, particularly in cases of co-ingestion with other agents or alcohol.


Immediate Action Required

Patients must seek emergency medical help immediately in case of a suspected or known overdose. The regulatory guidance for managing an overdose situation emphasizes establishing and maintaining an airway, ensuring adequate oxygenation, and closely monitoring cardiac and vital signs.

Specific procedural actions may include administering activated charcoal or performing gastric lavage, depending on the timing and presentation of the overdose. Induced emesis (vomiting) is generally not recommended as a treatment procedure.

Therapeutic Uses of Confer

What Confer Treats: Main Uses and Benefits

The primary role of Confer is to offer supportive therapeutic benefit focused on providing symptomatic relief across several key domains. It is specifically designed for use in situations involving certain distressing symptoms where they become noticeable, intense, or create increased discomfort or tension.

Confer is generally applied across conditions presenting with acute episodes and those characterized by episodic or fluctuating symptom patterns. It is commonly used when symptoms intensify and supportive relief is needed, particularly during phases where the patient experiences heightened discomfort. The medication helps address symptom clusters that may become intense or disruptive, such as those that interfere with daily comfort or create noticeable functional strain.

Relief Domains

The medication may assist with helping patients cope more steadily and supports functional stability when symptoms interfere with routine activities. This provides support that helps ease the overall symptom burden.

Quick Fact

Quick Fact: Relief for Acute Symptom Escalation

Confer contributes to easing the overall symptom load during periods of heightened symptoms, supporting patients when manifestations become temporarily overwhelming.

Eligibility and Restrictions for Use

Who Can and Cannot Use Confer?

The population eligibility for Confer (Ferrous Fumarate) is strictly defined by regulatory documents, which establish clear restrictions based on a patient’s medical status.

Populations for Whom Use Is Contraindicated

Confer must not be used by individuals with certain pre-existing conditions, as defined by official labeling:

  • Iron Overload: Patients with haemochromatosis, haemosiderosis, or other confirmed iron overload syndromes.
  • Anemia Type: Individuals with anaemias not caused by iron deficiency, such as haemolytic anaemia.
  • Gastrointestinal Disease: Patients with active peptic ulcer, regional enteritis, or ulcerative colitis.
  • Other Restrictions: Patients receiving repeated blood transfusions or those with a confirmed hypersensitivity to Ferrous Fumarate.

Age and Physiological Status

  • Adults and Older Adults are generally eligible for use in treating or preventing iron deficiency.
  • Pregnancy and Lactation: Use is permitted during both pregnancy and breastfeeding if clinically indicated.
  • Children: The tablet form is not intended for the treatment of children; alternative liquid formulations are generally advised.

Use requires caution in patients with a history of treated peptic ulceration or those post-gastrectomy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Confer, which contains Ferrous Fumarate, is primarily characterized by effects on absorption due to chelation and direct physiological interference as documented in official prescribing information.

Category
Medicinal product categories with documented interactions
Antibiotics (Quinolones, Tetracyclines), Bisphosphonates, Thyroxine, Anti-Parkinsonian agents, Immunosuppressants (Mycophenolate), Antihypertensives (Methyldopa), and certain chelating agents.

Official Interaction Statements:

  • Exposure Reduction of Other Medicines: Confer reduces the absorption and subsequent blood concentrations of several co-administered medicines, including Levothyroxine, bisphosphonates (like alendronic acid), and quinolone/tetracycline antibiotics. This interaction reduces the expected exposure to the co-administered drug.
  • Timing Separation Required: Regulatory documents mandate a separation of administration time for numerous interacting agents. For example, Levothyroxine must be separated by at least four hours from oral iron, while certain tetracyclines require separation by two or three hours to mitigate the absorption interference.
  • Formal Restrictions: Co-administration with Dimercaprol is subject to an official restriction and advised to be avoided due to the potential for enhanced nephrotoxic activity.
  • Pharmacodynamic Alteration: An interaction is documented where oral iron antagonises the hypotensive effect of co-administered Methyldopa.
  • Interactions with Food and Supplements: The absorption of Confer itself may be reduced by co-ingestion with antacids (containing aluminum or magnesium salts), Cholestyramine, tea, coffee, and dairy products. Conversely, Ascorbic Acid (Vitamin C) is documented to increase the absorption of oral iron.

The regulatory structure emphasizes that these interactions are mainly related to interference with oral absorption, necessitating strict compliance with timing constraints for numerous medicines to prevent documented reductions in exposure.

Mechanism of Action

How Confer Works

The pharmacodynamic action of Confer (Ferrous Fumarate) is one of substrate provision, designed to overcome a substrate deficit in key biological processes. Its mechanism is driven by the elemental iron ( Fe^2+) serving as a functional component in metalloproteins, rather than acting as a classical ligand for receptors or enzymes.

Restoring Oxygen-Carrying Capacity

The core mechanistic domain is the direct provision of Fe^2+ to the bone marrow. This iron is immediately bound to the transport protein Transferrin and delivered to developing red blood cells, where it is incorporated into Heme precursors to synthesize functional Hemoglobin (Hb). This process resolves the structural limitation in erythropoiesis, resulting in a corrected systemic oxygen-carrying capacity of the blood.

Supporting Cellular Energy Metabolism

Iron also acts as a vital cofactor for non-Hemoglobin enzymes, critically the Cytochromes located in the cell's mitochondria. By replenishing iron stores, the mechanism ensures the integrity of the electron transport chain, which is necessary for efficient oxidative phosphorylation and cellular ATP generation. The optimization of this fundamental metabolic process allows for efficient ATP generation across major organ systems.

Regulatory Constraints on Mechanism

The effectiveness of this replacement mechanism is subject to the body’s endogenous iron homeostasis. Elevated levels of the hormone Hepcidin can constrain the action of the drug by promoting the degradation of the iron exporter protein Ferroportin. This limits the flow of absorbed and stored iron into the bloodstream for utilization in Hemoglobin synthesis, thereby imposing a physiological constraint on the drug's pharmacodynamic action.

Dosage and Administration Information

Administration Protocol and Timing

The administration of Confer is strictly by the oral route, consistent with its preparation as a tablet or capsule. The goal of usage is iron replacement, which dictates a long-term treatment pattern based on restoring the body's iron stores. The medicine must be swallowed whole with water, without crushing, chewing, or splitting the dosage form unless explicitly stated otherwise in the product's instructions.


Official Dosing and Frequency

The dosing regimen is based on the quantity of elemental iron delivered by the preparation. For adults requiring treatment of established deficiency, the typical daily amount ranges from 100 mg to 200 mg of elemental iron. Lower doses, generally between 30 mg and 65 mg elemental iron daily, are used for prevention or maintenance purposes. The dosing frequency is usually once daily, although the total daily dose may be split into divided doses to improve patient tolerability.


Administration Conditions and Duration

To maximize the amount of iron absorbed, the medication is typically recommended to be taken on an empty stomach, such as one hour before or two hours after a meal. If this causes significant gastrointestinal discomfort, the dose may be taken with food, though this can diminish the amount absorbed. Standard instructions also stipulate avoiding co-administration with substances like antacids, dairy products, coffee, or tea, as these can interfere with iron absorption. If a dose is missed, patients are instructed not to take a double dose to compensate; the next scheduled dose should be taken at the usual time.


Course Length and Population Rules

Use of this medicine extends beyond the simple correction of hemoglobin levels. Treatment is a long-term plan and is typically continued for 3 to 6 months after blood concentrations return to the normal range to ensure complete replenishment of systemic iron reserves. For children, dosing involves a specialized, weight-based calculation and is not derived from adult regimens.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Confer (Ferrous Fumarate)


Evidence for Use in Iron Deficiency Anemia (IDA)

Research exploring iron salts like Ferrous Fumarate has been conducted using established methods, primarily Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies included non-pregnant adults diagnosed with Iron Deficiency Anemia (IDA). The research was studied for how the medicine was observed in trials that monitored physiological strain related to low iron, focusing on outcomes related to systemic or functional imbalance.

The research examined changes in Hematological Biomarkers over short- to intermediate-term follow-up periods, typically around 8 to 12 weeks. Studies monitored shifts in key levels, such as Hemoglobin (Hb) and Serum Ferritin, which reflects the body’s iron stores. Research highlights changes measured during the study period, consistent with patterns observed in iron replacement research. These findings describe patterns observed in the studies and help contextualize the evolution of iron status.

Evidence for Iron Deficiency Without Anemia (IDWA)

Research has explored the role of oral iron in individuals with Iron Deficiency Without Anemia (IDWA)—meaning they have low iron stores but their hemoglobin levels are still considered normal. Studies have included placebo-controlled trials examining adults who present with outcomes related to physical discomfort or fatigue.

These trials was studied for how symptoms change over time, specifically using standardized measures like Fatigue scales and tests of Cognitive Function. Studies report how symptoms evolved in the observed populations in relation to iron administration, and research describes some patterns observed in the studies related to fatigue. However, findings were mixed across studies concerning the impact on specific cognitive endpoints.

Evidence for Prophylactic Use During Pregnancy

The use of iron for preventive purposes (prophylaxis) during pregnancy was evaluated in Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies focused on healthy pregnant women and research examined how iron administration influenced the incidence of maternal iron deficiency at the time of delivery.

What is Still Uncertain About Confer

There are acknowledged research limitations and gaps. For instance, the evidence quality varies across studies focusing on subjective symptoms like fatigue, making the certainty remain low in some areas. Findings were mixed across trials that measured these non-specific outcomes, making interpretation challenging. Furthermore, comparative evidence is lacking across all available iron formulations, meaning results apply only to the populations studied and the specific conditions under which they were conducted.

Key Studies & References A randomized controlled trial of thrice-weekly versus thrice-daily oral ferrous fumarate treatment in adult patients with iron-deficiency anemia

Frequently Asked Questions (FAQ)

Common questions about Confer (FAQ)


Q: Is it true that Confer has a low risk of dependency?

According to official regulatory records, Ferrous Fumarate, the active ingredient in Confer, is an iron salt. It is not classified as a controlled substance or scheduled drug in major jurisdictions. Official classification indicates that the medicine is not generally associated with dependency or abuse risk.


Q: How long does the effect of Confer last after taking it?

The physical process of absorbing the elemental iron from Confer occurs over several hours after a dose. Once absorbed, the iron is used to support the production of red blood cells. Since this is a biological building process, the overall therapeutic effect is cumulative and long-term, not an immediate or short-lasting effect.


Q: Has Confer been available for a long time, or is it a new medicine?

Official documents indicate that Ferrous Fumarate, the active ingredient in Confer, is a well-established medicinal product. It is included on the World Health Organization’s List of Essential Medicines. This international recognition confirms its long-standing and established role in nutritional iron replacement therapy.


Q: Is Confer a narcotic or controlled substance?

The active substance, Ferrous Fumarate, is classified as an iron salt and is not listed as a narcotic or a controlled substance under regulatory laws in major jurisdictions.


Q: Can taking Confer affect my ability to drive or operate machinery?

Official regulatory documents for iron supplements typically state that they do not affect a person's ability to drive or operate heavy machinery. However, official documents recommend monitoring the body’s response, as side effects like dizziness or fatigue are possible.


Q: Does Confer need to be taken at a specific time of day?

Regulatory guidance prioritizes taking the dose relative to food, such as on an empty stomach, to maximize iron absorption. The instructions do not usually specify that the dose must be taken at a certain time of day, like morning versus evening. Consistency in timing relative to meals is usually emphasized.


Q: Are there any known issues with Confer and heart conditions?

Confer is strictly contraindicated in patients who have confirmed conditions that cause iron overload, such as hemochromatosis. Conditions of iron overload are known to potentially affect organs like the heart. This restriction indicates the need for careful consideration for individuals with specific pre-existing conditions.


Q: Can lifestyle factors like smoking or alcohol impact how Confer works?

Official information generally indicates that the use of oral iron is not restricted by alcohol consumption. Alcohol is not specifically listed as a substance known to impact the medicine’s effectiveness. Smoking is also not typically addressed in the official interaction statements.


Q: What is the shelf life of Confer before it expires?

The specific shelf life of Confer is determined by the manufacturer to ensure the stability of the active ingredient. This date is stated as the 'expiry date' on the outer packaging and on the container itself. Based on regulatory guidance, the product is not intended for use after this time.


Q: Is it possible for Confer to become less effective over time?

Official information describes how the body naturally regulates iron levels using a hormone called Hepcidin. This hormone can temporarily limit iron absorption after a dose, which may reduce the amount of iron utilized by the body. However, this is described as a physiological constraint and not a loss of drug effectiveness over the long term.


Q: Is Confer safe to use if I am also taking an antidepressant?

Official prescribing documents detail interactions with several major drug categories, but specific interactions with most common antidepressants are not universally listed. Oral iron is known to interfere with the absorption of other medicines. For this reason, regulatory guidance often suggests a separation in administration times to mitigate potential interference with the absorption of other medicines.


Q: What are the common reasons people stop using Confer?

Based on official summaries of safety profiles, the most frequent reason people discontinue using oral iron supplements is due to gastrointestinal (GI) side effects. These effects, which include nausea, diarrhea, or constipation, are often reported to be dose-dependent during clinical trials.

How should Confer be stored and disposed of?

How to Store and Dispose of Confer (Ferrous Fumarate)

Confer must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), to maintain its stability and shelf life. The medication requires protection; keep it in the original container, tightly closed, and store it away from light, excess heat, and moisture. Storing the product in environments like the bathroom is prohibited.


Child Safety and Disposal

A critical storage requirement is to keep Confer out of the sight and reach of children, as iron overdose can be fatal. For disposal, unused or expired Confer tablets must not be flushed down the toilet. Instead, it should be disposed of via a medicine take-back program or, if unavailable, mixed with an undesirable substance and placed in a sealed bag before being thrown in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Confer found in:

A-Z Index: